Pharmacokinetic, docking, and DFT analyses reveal Moringa oleifera phytochemicals as inhibitors of HIF-1α/VEGF/GLUT1 signaling pathway in breast cancer
Abstract
Breast cancer is among the most heterogeneous and aggressive malignancies. Hypoxia-driven activation of Hypoxia-inducible factor-1 alpha (HIF-1α) in breast cancers triggers the transcription of a battery of genes that facilitate tumor progression and result in poor prognosis. Based on the reported anti-cancer properties of Moringa oleifera (Mo), this study explores the therapeutic effects of isolated bioactive compounds from Mo, namely Aurantiamide Acetate (AA) and Benzyl Isothiocyanate (BITC), on HIF-1α-regulated key genes- vascular endothelial growth factor (VEGF) and glucose transporter 1 (GLUT1), targeting the HIF-1α/VEGF/GLUT1 axis, which is central to angiogenesis and metabolic adaptation in tumors using a comprehensive in silico approach. The X-ray crystallographic structures of HIF-1α, VEGF, and GLUT1 were retrieved from PDB and employed as receptor targets for molecular docking studies against 3D conformers of AA and BITC using AutoDock Vina to evaluate their binding affinity and interaction profiles. Post-docking conformational analyses were conducted utilizing Discovery Studio. The pharmacological relevance of the compounds was assessed using SwissADME, ADMETSaR, and ADMETlab3.0 web servers for drug-likeness, oral bioavailability, and ADMET profiles. Subsequently, robust molecular dynamics simulations were executed for 500 nanoseconds using the Desmond module (Schrödinger v2019) to evaluate the structural stability of the ligand-receptor complexes under…
Read the paper
Related studies
- Chaos and quantum thermalization
- The Dalton quantum chemistry program system
- Cord Blood Leptin and Adiponectin as Predictors of Adiposity in Children at 3 Years of Age: A Prospective Cohort Study
- Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes
- Stable adiabatic quantum batteries
- A novel self-lipid antigen targets human T cells against CD1c(+) leukemias
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.